Market Overview:
The global prostate cancer diagnostics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of prostate cancer, technological advancements in prostate cancer diagnostics, and increasing demand for early diagnosis and treatment of prostate cancer. Based on type, the global prostate cancer diagnostics market is segmented into tumor biomarker tests, imaging, biopsy, and other tests. The tumor biomarker tests segment is expected to account for the largest share of the global market in 2018. This can be attributed to the growing use of tumor biomarkers for early detection and diagnosis of prostate cancer. Based on application, the global market is divided into three segments: age < 55 years old; age 55-75 years old; and age > 75 years old.
Product Definition:
Prostate cancer diagnostics is the process of detecting and diagnosing prostate cancer. It involves a number of tests and procedures, including a digital rectal examination (DRE), a blood test for prostate-specific antigen (PSA), an ultrasound exam, and a biopsy. Prostate cancer diagnostics is important because it allows doctors to identify and treat prostate cancer at an early stage, when the chances for successful treatment are greatest.
Tumor Biomarker Tests:
Tumor biomarker tests are laboratory tests that measure the presence of certain substances in tumors, which are released by the body as a response to injury or trauma. These substances can act as tumor markers orbiomarkers and help diagnose various types of cancers. Some commonly used biomarkers include CA-125 (caustic soda test), PSA (prostate specific antigen), and HbA1c (glycosylated hemoglobin).
Imaging:
Imaging techniques are used for the detection of prostate cancer. Imaging techniques include ultrasound, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, and X-ray. The choice of imaging technique depends on several factors such as patient age, presence or absence of symptoms at the time of diagnosis, physician preference and experience with a particular imaging technique among others.
Application Insights:
The age group of 55 to 75 years held the largest share of over 50.0% in 2017. This is due to the increasing prevalence of prostate cancer and rising demand for more effective treatment options across this demographic. For instance, according to data published by the U.S National Cancer Institute, around 1 in 6 men aged 65 or above were diagnosed with prostate cancer in 2016 compared with 1 in 17 men aged 55 to 64 years and less than 1 in 25 men aged 35 to 54 years.
Furthermore, a rise was observed among young people (aged 18-24) regarding screening for prostate cancer; however, this can be attributed towards early detection programs conducted through PSA testing which has resultedantly increased awareness about early diagnosis among this demographic group as well as others at high risk of developing aggressive forms of the disease.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced diagnostic technologies, and rising incidence rates of prostate cancer. In addition, government initiatives and funding programs are also responsible for its large share. For instance, as per a recent study by National Cancer Institute (NCI), from 2009 to 2011, NCI invested around USD X million in Prostate Cancer Biomarkers Research Consortium (PCBRC).
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to increasing prevalence rates coupled with growing awareness about early diagnosis leading towards better treatment options. Moreover, economic development in this region has resulted in an increase in healthcare spending by local populace which is further fueling growth over next eight years.
Growth Factors:
- Increasing incidence of prostate cancer
- Growing awareness about prostate cancer and its early detection methods
- Rising demand for minimally invasive diagnostic procedures
- Technological advancements in prostate cancer diagnostics
- Growing number of collaborations and partnerships between diagnostic companies and research institutes
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Cancer Diagnostics Market Research Report
By Type
Tumor Biomarker Tests, Imaging, Biopsy, Other
By Application
age < 55, age 55-75, age > 75
By Companies
Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, BioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Cancer Diagnostics Market Report Segments:
The global Prostate Cancer Diagnostics market is segmented on the basis of:
Types
Tumor Biomarker Tests, Imaging, Biopsy, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
age < 55, age 55-75, age > 75
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genomic Health
- Abbott
- OPKO
- Siemens Healthcare
- DiaSorin
- BioMeriux
- Roche
- MDx Health
- Beckman Coulter
- Myriad Genetics
- Ambry Genetics
Highlights of The Prostate Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
- By Application:
- age < 55
- age 55-75
- age > 75
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate cancer diagnostics is a term used to describe the various tests and procedures that are used to diagnose prostate cancer. These tests can include blood work, imaging scans, and biopsies.
Some of the major companies in the prostate cancer diagnostics market are Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, BioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics.
The prostate cancer diagnostics market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prostate Cancer Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prostate Cancer Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prostate Cancer Diagnostics Market - Supply Chain
4.5. Global Prostate Cancer Diagnostics Market Forecast
4.5.1. Prostate Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prostate Cancer Diagnostics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Prostate Cancer Diagnostics Market Absolute $ Opportunity
5. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
5.3.1. Tumor Biomarker Tests
5.3.2. Imaging
5.3.3. Biopsy
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
6.3.1. age < 55
6.3.2. age 55-75
6.3.3. age > 75
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Prostate Cancer Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Prostate Cancer Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029
9. North America Prostate Cancer Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
9.4.1. age < 55
9.4.2. age 55-75
9.4.3. age > 75
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
9.7.1. Tumor Biomarker Tests
9.7.2. Imaging
9.7.3. Biopsy
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029
10. Latin America Prostate Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
10.4.1. age < 55
10.4.2. age 55-75
10.4.3. age > 75
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
10.7.1. Tumor Biomarker Tests
10.7.2. Imaging
10.7.3. Biopsy
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Prostate Cancer Diagnostics Demand Share Forecast, 2019-2029
11. Europe Prostate Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
11.4.1. age < 55
11.4.2. age 55-75
11.4.3. age > 75
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
11.7.1. Tumor Biomarker Tests
11.7.2. Imaging
11.7.3. Biopsy
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Prostate Cancer Diagnostics Demand Share, 2019-2029
12. Asia Pacific Prostate Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
12.4.1. age < 55
12.4.2. age 55-75
12.4.3. age > 75
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
12.7.1. Tumor Biomarker Tests
12.7.2. Imaging
12.7.3. Biopsy
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Prostate Cancer Diagnostics Demand Share, 2019-2029
13. Middle East & Africa Prostate Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Application
13.4.1. age < 55
13.4.2. age 55-75
13.4.3. age > 75
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Prostate Cancer Diagnostics Market Size and Volume Forecast by Type
13.7.1. Tumor Biomarker Tests
13.7.2. Imaging
13.7.3. Biopsy
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Prostate Cancer Diagnostics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Prostate Cancer Diagnostics Market: Market Share Analysis
14.2. Prostate Cancer Diagnostics Distributors and Customers
14.3. Prostate Cancer Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Genomic Health
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Abbott
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. OPKO
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Siemens Healthcare
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. DiaSorin
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMeriux
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. MDx Health
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Beckman Coulter
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Myriad Genetics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Ambry Genetics
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook